文献速递神经重症

神经重症患者补充维生素D对结局的影响:RECTIFY随机对照试验

The effect of supplementation of vitamin D in neurocritical care patients: RandomizEd Clinical TrIal oF hYpovitaminosis D (RECTIFY).
PubMed 文献 · J Neurosurg · 2019-09-13

这项单中心、双盲、安慰剂对照、1:1随机临床试验纳入维生素D缺乏(≤20 ng/ml)的急诊神经重症患者,比较单次大剂量维生素D3(胆钙化醇540,000 IU)与安慰剂对结局的影响。因期中分析提示条件把握度低(预测把握度0.12),试验提前终止;按实际治疗分析未发现住院时长或ICU住院时长显著差异,但复测血清维生素D水平显著提高且无不良副作用。

要点

  • 神经重症维生素D缺乏患者补充维生素D3未改善住院时长或ICU住院时长。
  • 补充维生素D3可显著提高复测血清维生素D水平,且未观察到不良副作用。
  • 因期中分析提示条件把握度低(预测把握度0.12),该试验提前终止。

核心结论

  • 在维生素D缺乏的神经重症患者中,补充维生素D未带来结局的明显改善,可能不参与急性临床恢复。

研究设计与样本

  • 单中心、双盲、安慰剂对照、1:1随机临床试验;2016年10月至2018年4月纳入急诊入院的维生素D缺乏(≤20 ng/ml)神经重症患者。
  • 主要结局为住院时长(LOS);次要结局包括ICU住院时长、复测维生素D水平、患者并发症及患者去向。
  • 探索性分析按住院时长、格拉斯哥昏迷评分(GCS)、简化急性生理评分(SAPS II)评估特定亚组。

主要发现

  • 按实际治疗分析,维生素D3组与安慰剂组住院时长分别为10.4 ± 14.5天与9.1 ± 7.9天,p=0.4,平均差1.3,95%CI -1.5至4.1。
  • 按实际治疗分析,维生素D3组与安慰剂组ICU住院时长分别为5.8 ± 7.5天与5.4 ± 6.4天,p=0.4,平均差0.4,95%CI -1.3至2.1。
  • 维生素D3组复测血清维生素D水平显著高于安慰剂组(20.8 ± 9.3 ng/ml vs 12.8 ± 4.8 ng/ml,p<0.001),且无不良副作用。
  • 排除住院时长离群值或按GCS评分、SAPS II、严重维生素D缺乏(≤10 ng/ml)分层均未识别出特定亚组。

关键数值与推荐

  • 维生素D缺乏定义为血清维生素D ≤20 ng/ml;严重维生素D缺乏定义为≤10 ng/ml。
  • 维生素D3(胆钙化醇)剂量为540,000 IU,单次给药。
  • 主要结局住院时长在两组间无显著差异(p=0.4,平均差1.3,95%CI -1.5至4.1)。
  • ICU住院时长在两组间无显著差异(p=0.4,平均差0.4,95%CI -1.3至2.1)。
  • 复测血清维生素D水平组间差异显著(20.8 ± 9.3 ng/ml vs 12.8 ± 4.8 ng/ml,p<0.001)。

临床怎么用

  • 对维生素D缺乏的神经重症患者,急性期单次大剂量补充维生素D3虽能提高血清水平,但不应期望借此缩短住院或ICU时长。
  • 补充维生素D3在该人群中未观察到不良副作用,可作为纠正维生素D缺乏的实验室指标手段,但需结合整体临床管理判断其价值。

局限性

  • 试验因期中分析提示条件把握度低(预测把握度0.12)而提前终止,实际给药例数为计划招募的61.2%,可能影响统计效能。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hypovitaminosis D is prevalent in neurocritical care patients, but the potential to improve patient outcome by replenishing vitamin D has not been investigated. This single-center, double-blinded, placebo-controlled, randomized (1:1) clinical trial was designed to assess the effect on patient outcome of vitamin D supplementation in neurocritical care patients with hypovitaminosis D. METHODS: From October 2016 until April 2018, emergently admitted neurocritical care patients with vitamin D deficiency (≤ 20 ng/ml) were randomized to receive vitamin D3 (cholecalciferol, 540,000 IU) (n = 134) or placebo (n = 133). Hospital length of stay (LOS) was the primary outcome; secondary outcomes included intensive care unit (ICU) LOS, repeat vitamin D levels, patient complications, and patient disposition. Exploratory analysis evaluated specific subgroups of patients by LOS, Glasgow Coma Scale (GCS) score, and Simplified Acute Physiology Score (SAPS II). RESULTS: Two-hundred seventy-four patients were randomized (intent-to-treat) and 267 were administered treatment within 48 hours of admission (as-treated; 61.2% of planned recruitment) and monitored. The mean age of as-treated patients was 54.0 ± 17.2 years (56.9% male, 77.2% white). After interim analysis suggested a low conditional power for outcome difference (predictive power 0.12), the trial was halted. For as-treated patients, no significant difference in hospital LOS (10.4 ± 14.5 days vs 9.1 ± 7.9 days, p = 0.4; mean difference 1.3, 95% CI -1.5 to 4.1) or ICU LOS (5.8 ± 7.5 days vs 5.4 ± 6.4 days, p = 0.4; mean difference 0.4, 95% CI -1.3 to 2.1) was seen between vitamin D3 and placebo groups, respectively. Vitamin D3 supplementation significantly improved repeat serum levels compared with placebo (20.8 ± 9.3 ng/ml vs 12.8 ± 4.8 ng/ml, p < 0.001) without adverse side effects. No subgroups were identified by exclusion of LOS outliers or segregation by GCS score, SAPS II, or severe vitamin D deficiency (≤ 10 ng/ml). CONCLUSIONS: Despite studies showing that vitamin D can predict prognosis, supplementation in vitamin D-deficient neurocritical care patients did not result in appreciable improvement in outcomes and likely does not play a role in acute clinical recovery.Clinical trial registration no.: NCT02881957 (clinicaltrials.gov).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Karsy M, Guan J, Eli I, et al. The effect of supplementation of vitamin D in neurocritical care patients: RandomizEd Clinical TrIal oF hYpovitaminosis D (RECTIFY). J Neurosurg. 2019. PMID: 31518978. doi:10.3171/2018.11.JNS182713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。